Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology.
The eleventh volume of this series features reviews that cover the following topics related to the treatment of a variety of CNS disorders, related diseases, and basic research:
- The Multi-target Directed Ligands candidate (MTDLs) prototypes for neurodegenerative diseases
- Drugs for relapse prevention in addiction
- Neuroprotective activities of cinnamic acids and their derivatives in neurodegenerative disorders
- Phytosome for targeted delivery of natural compounds in treating alzheimer's disease
- Physical activity as a non-pharmacologic method for treatment of alzheimer’s disease
Pharmaceutical scientists, clinical researchers, medical consultants and allied healthcare professionals interested in neuropharmacology and neurology.